BRAF and MEK inhibitors—represented here by dabrafenib and trametinib—were small-molecule agents that blocked the MAPK (RAF–MEK–ERK) pathway and were commonly used in combination in BRAF V600E–mutant NSCLC (4). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.